TP53 and leukoplakia: While only 6 of 20 (30%) patients in that molecular study were characterized as having proliferative leukoplakia, other studies aimed at genotyping the proliferative leukoplakia subgroup have nominated alterations in TP53 and CDKN2A as important (24, 25).